# CORRELATION OF BREAST CANCER AND SERUM HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL: A SINGLE CENTRE STUDY

Anjali Sethi<sup>1</sup>, Deepak Sethi<sup>2</sup>

<sup>1</sup>Assistant Professor, Department of General Surgery, Ananta Institute of Medical Sciences and Research Center, Kaliwas, Nathdwara, District, Rajsamand (Rajasthan), India.

Consultant and J. S, Department of General Surgery, Rabindranath Tagore Medical College, Udaipur (Rajasthan), India.

ABSTRACT

Breast cancer is the most common site specific cancer in women. Lots of etiological factors have been suggested regarding its causation. The risk is influenced by obesity, parity, exogenous and endogenous hormones, exposure to chemicals and radiation and many more. Various studies suggest that as HDL-C seems to be cardio protective, it is also protective for breast cancer. Serum HDL-C levels are found to be low in breast cancer patients. We studied this hypothesis in local population of Southern Rajasthan and nearby region to see if low serum HDL-C is associated with increased risk of breast cancer. We studied serum HDL-C level in 50 female patients of breast cancer along with their menopausal status and compared it to their respective controls. We found that breast cancer patients had significantly low level of serum HDL-C and presented in advanced stage of cancer. It supports that low serum HDL-C level is associated with increased risk of breast cancer. So one should think about those dietary and lifestyle measures, which maintain high serum HDL-C level so that it might become preventive measure for breast cancer.

## **KEYWORDS**

Breast Cancer, High Density Lipoprotein Cholesterol, Risk Factors, Pre-menopausal, Post-menopausal.

**HOW TO CITE THIS ARTICLE:** Anjali Sethi, Deepak Sethi. "Correlation of Breast Cancer and Serum High Density Lipoprotein Cholesterol Level: A Single Centre Study." Journal of Evolution of Medical and Dental Sciences 2015; Vol. 4, Issue 97, December 03; Page: 16224-16228, DOI: 10.14260/jemds/2015/2388

#### **INTRODUCTION**

Breast Cancer is the most common site specific cancer in women and a leading cause of death due to cancer between 40-45 years of age. It has now become a global disease. It accounts for 33% of all female cancer and 20% of cancer related death in women.

The exact cause of breast cancer is not known but sex hormones, both endogenous and exogenous play an important role. Exposure to radiation and chemicals can also stimulate the onset of disease.<sup>(1)</sup> The risk of breast cancer is also influenced by dietary fat intake, obesity, parity, duration of breast feeding, family history and socio-economic status.<sup>(2)</sup> Breast cancer is considered to be consequences of high fat consumption.

There may be chemical carcinogen in fatty fried diet and altered bacterial flora in intestine leads to increased production of carcinogenic substances. Serum lipid profile is an important marker of dietary fat intake.<sup>(2)</sup> Various studies indicate that plasma triglycerides and LDL-C levels were found to be significantly elevated among breast cancer patients.,<sup>(3)</sup> but HDL-C level were observed to be significantly low as compared to control.<sup>(1,4,5)</sup> It raises a question that HDL-C seems to be protective in breast carcinogenesis.

Serum HDL-C levels are found to be low in breast cancer patients. We studied this hypothesis to see if low serum HDL-C is associated with increased risk of breast cancer.

Financial or Other, Competing Interest: None.
Submission 17-11-2015, Peer Review 18-11-2015,
Acceptance 26-11-2015, Published 01-12-2015.
Corresponding Author:
Dr. Anjali Sethi,
303, Akshansh Apartment,
Keshav Nagar-313001, Udaipur.
E-mail: deepanjali.a1976@gmail.com
D01:10.14260/jemds/2015/2388

We studied the correlation between serum HDL-C (HDL) level and female breast cancer and clinical staging in local population of Southern Rajasthan and nearby region in the patients who consulted to our Tertiary Care Level Hospital.

#### ABBREVIATIONS

HDL-C (HDL)–High Density Lipoprotein Cholesterol LDL–Low Density Lipoprotein VLDL–Very Low Density Lipoprotein USG–Ultrasonography FNAC–Fine Needle Aspiration Cytology CL–Confidence Limit SR-BI–Scavenger receptor class B type I.

## METHOD AND MATERIAL

We studied 50 patients of breast cancer. Patients were diagnosed on basis of detailed history, clinical examination, mammography, USG, FNAC, and Tru-Cut biopsy. Lifestyle parameters like socio-economic status, age of menarche, menopausal status, use of oral contraceptives, hormone replacement therapy, etc., were also evaluated.

HDL (HDL-C) was estimated in venous blood samples of patients. Blood sample of 50 controls were also analyzed for HDL-C. Controls were those females who were not suffering from breast cancer, but fell in same age group. HDL-C was detected in lab by direct homogenous assay method.

Females who presented in stage I and II were included in early stage and those in stage III and IV were included in advanced stage.

### **Expected Normal Range**

Adult Male-54.5±12.9mg/dl Adult Female-61.2±12.3mg/dl

## Jemds.com

## **OBSERVATION AND DISCUSSION**

When we explored our data, we found that mean age of breast cancer patients was 48.32 years (Control 49.96 years). Out of 50 patients who entered in our study, 48% were premenopausal (Control-46%) and 52% were post-menopausal (Control 54%). Among these patients 44% presented in early stage (Stage I and II) of cancer and 56% in advanced stage (Stage III and IV) (Table 1, 2, 3).

When we analyzed HDL-C level in our patient, we found that mean HDL-C level in patient was 41.83mg% (Control 46.11mg%). In pre-menopausal patients mean HDL-C was 41.67mg% (Control 45.59mg%) and in post-menopausal patients mean HDL-C was 41.99mg% (Control 46.72mg%) (Table 4, 5) (Graph 1, 2, 3 and 4).

We found a significant difference in HDL-C level in breast cancer patient and their control (p<0.05; 95% CL), but no relation was seen with respect to menopausal status. It suggests that low HDL level is associated with increased risk of breast cancer in local population of Southern Rajasthan and nearby region irrespective of menopausal status.

For post-menopausal women, our findings are similar to Furberg who suggested that the risk of breast cancer was inversely related to highest quartile v/s lowest quartile.<sup>(6)</sup> Hoyer found a relative risk of 0.3/women in highest quartile of HDL-C compared to those of lowest quartile.<sup>(7)</sup>

Various other studies also support our findings related to HDL-C and breast cancer.<sup>(8,9)</sup> Contrary to it Moorman found a positive association between HDL-C and post-menopausal breast cancer, but an inverse association in pre-menopausal women.<sup>(10)</sup> Tretli found no such association.<sup>(11)</sup> Ferraroni showed a tendency towards higher level of HDL-C among premenopausal women.<sup>(12)</sup>

Lipoproteins are large macromolecular complexes that transport hydrophobic lipids (Primarily triglycerides, cholesterol, and fat-soluble vitamins) through body fluids (Plasma, interstitial fluid, and lymph) to and from tissues. Lipoproteins play an essential role in the absorption of dietary cholesterol, long-chain fatty acids, and fat-soluble vitamins; the transport of triglycerides, cholesterol, and fatsoluble vitamins from the liver to peripheral tissues; and the transport of cholesterol from peripheral tissues to the liver. Lipoproteins contain a core of hydrophobic lipids (Triglycerides and cholesteryl esters) surrounded by hydrophilic lipids (Phospholipids, unesterified cholesterol) and proteins that interact with body fluids.

The plasma lipoproteins are divided into five major classes based on their relative density: chylomicrons, Very Low-Density Lipoproteins (VLDLs), Intermediate-Density Lipoproteins (IDLs), Low-Density Lipoproteins (LDLs), and High-Density Lipoproteins (HDLs). Each lipoprotein class comprises a family of particles that vary slightly in density, size and protein composition.

The density of a lipoprotein is determined by the amount of lipid per particle. HDL is the smallest and most dense lipoprotein, whereas chylomicrons and VLDLs are the largest and least dense lipoprotein particles. Most plasma triglyceride is transported in chylomicrons or VLDLs and most plasma cholesterol is carried as cholesteryl esters in LDLs and HDLs.<sup>(13)</sup>

HDL is synthesized and secreted from liver and intestine. HDL is an important component of metabolism and may influence the risk of breast cancer in women with positive energy balance.<sup>(6)</sup> Its level is affected by various factors like dietary fat intake, alcohol consumption, endogenous hormones and pre-menopausal leanness. Increase in any of these factors is known to increase the level of HDL-C. HDL-C appears to possess biological properties that may be relevant to carcinogenesis.<sup>(14)</sup> HDL-C has a great potential to counter the oxidative damage in cell membrane by preventing lipid peroxidase and act as antioxidant and anticarcinogen. Because plasma HDL-C level are decreased they are not sufficient enough to counter ROM attach thereby resulting in higher oxidative stress, which may cause cellular and molecular damage leading to cell proliferation and malignant transformation of mammary cells.<sup>(9)</sup>

Borreli found that breast cancer patient had higher concentration of HDL-C, both in pre- and post-menopausal women. This could be explained by an increased oestrogenic activity and its role in modulation of lipid metabolism.<sup>(15)</sup> Sex hormones affect HDL-C level by regulating two enzymes namely lipoprotein lipase and hepatic endothelial lipase.<sup>(16)</sup> Androgen lowers the plasma HDL and increase LDL level. Oestrogen has opposite effect by rising HDL and lower LDL level. After menopause as oestrogen level falls, HDL level also decreases.<sup>(17)</sup>

HDL stimulates the proliferation of human breast cell, especially in hormone independent cells.<sup>(18)</sup> Frank exposed breast cancer cell lines to HDL and noticed that signaling pathways involved in cancer progression were activated and that the cells began to migrate in an experimental model mimicking metastasis. The study supports the idea that HDL plays a role in development of aggressive breast cancers and that inhibiting its function via SR-BI in breast cancer cells may stall cancer growth.<sup>(19)</sup> It suggests that HDL and SR-BI have a pro-oncogenic activity and can act as a potential target for treatment of breast cancer.<sup>(20)</sup>

#### SUMMARY

In our study we found that serum HDL-C level was significantly low in breast cancer patients and the finding was more pronounced in patients with advanced disease. HDL-C and breast cancer, both are influenced by dietary fat intake, weight, pregnancy, endogenous hormone, smoking, physical activity and socio-economic status.

World cancer research and American Institute of Cancer Research have estimated that incidence of cancer in worldwide could be reduced to 30-40% by dietary modification. BMI should be in range of 18.5-25. Fruits and vegetables should provide 7% or more of energy intake. Protein and starchy food should provide 45-60% of total energy.

In local population of Southern Rajasthan and nearby region we found that menarche was late, women were usually mulitparous; fed their babies for a long time. They usually did not use exogenous hormones. Most of them were physically active involving in farming and household works and were thin built. They ate lesser amount of fruits, vegetables and fiber diet; and usually ate maize and wheat as their staple food.

We found that low serum HDL-C level is associated with increased breast cancer risk. High HDL-C seems to be protective for breast cancer. So we should think about those dietary and lifestyle measures, which maintain high HDL-C level in blood, so that it may be used as a preventive measure for breast cancer.

## Jemds.com

## BIBLIOGRAPHY

- 1. Paley PJ. Screening for major malignancy affecting women: current guideline. Am J obstet Gynecol 2001;184(5):1021-30.
- Laisupasin P, et al. Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians 2013 Jan;5(1):38-41.
- 3. Kiran Hasija, Hardeep K Bagga. Alterations of serum cholesterol and serum lipoproteinin breast cancer of women. Indian J Clin Biochem 2005 Jan;20(1):61-66.
- 4. Anna M. Kucharska-Newton et al. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008 Sep;18(9):671-677.
- Araki E, Yamamoto H. Serum HDL-Cholesterol in patient with breast carcinoma. Rinsho Byori 1992 Mar;40(3):326-8.
- 6. Furberg AS, Veierod MB, et al. (2004 Aug). Serum highdensity lipoprotein cholesterol, metabolic profile and breast cancer risk. J Natl Cancer Inst 2004 Aug;96(15):1152-60.
- 7. Hoyer AP, Engholm G (1992 Sep). Serum lipids and breast cancer risk: a cohort study of 5207 Danish women. Cancer Causes Control 1992 Sep;3(5):403-8.
- 8. Schreier LE, Berg GA, et al. (1999 Apr). Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 1999 Apr;47(4):681-90.
- 9. Ray G, Hussain SA (2001 Feb). Role of Lipids, Lipoproteins and vitamins in women with breast cancer. Clin Biochem 2001 Feb;34(1):71-6.
- 10. Moorman PG, Hulka BS, et al. (1998 Jun), Association between High Density Lipoprotein Cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 1998 Jun;7(6):483-8.
- 11. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 1994 Nov;5(6):501-9.

- 12. Ferraroni M, Gerber M, et al. (1993 Oct). HDL Cholesterol and breast cancer: a joint study in Northern Italy and Southern France. Int J Epidemiol 1993 Oct;22(5):772-80.
- Daniel J Rader, Helen H Hobbs (2011). Disorders of Lipoprotein Metabolism. Harrison's Principles of Internal Medicine 18th Edition Page 3145.
- 14. Boyd NF, McGuire V. Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst 1990;82:460–8.
- 15. Borrelli R, del Sordo G, et al. (1993). High HDL-Cholesterol in pre- and post-menopausal women with breast cancer in Southern Italy. Adv Exp Med Biol 1993;348:149-53.
- 16. Semmens J, Rouse I, et al. (1983 May). Relationship of plasma HDL-Cholesterol to testosterone, estradiol and sex-hormone-binding globulin levels in men and women. Metabolism 1983 May;32(5):428-32.
- Gillmer MD (1992). Mechanism of action/effect of androgens on lipid metabolism. Int J Fertil 1992;37(Suppl 2):83-92.
- 18. Rotheneder M, Kostner GM (1989 May). Effect of lowand high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer 1989 May;43(5):875-9.
- Philippe Frank (1993). Thomas Jefferson University. "Does good cholesterol increase breast cancer risk?" Science Daily, 9 October 2013. www.sciencedaily.com/releases/2013/10/131009105 753.htm.
  - 20. Danilo C, Jorge LGP, et al. (2013 March). Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Research 2013;15:R87.

Age of Breast Cancer Patients and Controls						
A = -	Case	es (n = 50)	Controls $(n = 50)$			
Age	Ν	%	Ν	%		
<30	3	6.00	0	0.00		
31-40	12	24.00	11	22.00		
41-50	18	36.00	21	42.00		
51-60	11	22.00	11	22.00		
>60	6	12.00	7	14.00		
Total	50	100.00	50	100.00		
Table 1						

	-	al Status of Breast ents and Controls	Cancer		
Manager and States	C	ases	Controls		
Menopausal Status	Ν	%	Ν	%	
Pre-menopausal	24	48.00	23	46.00	
Post-menopausal	26	52.00	27	54.00	
Total	50	100.00	50	100.00	
		Table 2			

## Jemds.com

Staging of Breast Cancer v/s Menopausal Status							
Stage	Pre-menopausal (n=24)		Post-menopausal (n=26)		Total		
	Ν	%	Ν	%	Ν	%	
Stage I $(n = 0)$	0	0	0	0	0	0	
Stage II (n=22)	7	29.1	15	57.1	22	44.0	
Stage III (n=16)	10	41.6	6	23.0	16	32.0	
Stage IV (n=15)	7	29.1	5	19.8	12	24.0	
Total	24	100.0	26	100.0	50	100.00	
Table 3							

HDL Level V/s Staging in Pre- and Post-menopausal Breast Cancer Patients								
	Pre-menopausal				Post-Menopausal			
			Total				Total	
HDL Level	Early Stage	Advance Stage	N	%	Early Stage	Advance Stage	N	%
<=40	3	11	14	58.30	7	6	13	50.0
41-45	3	2	5	20.80	6	1	7	26.92
46-50	0	2	2	8.33	0	2	2	7.69
51-55	0	0	0	0.00	0	1	1	3.85
>55	1	2	3	12.50	2	1	3	11.54
Total	7	17	24	100.00	15	11	26	100.00
Table 4								

HDL Level of Controls								
Pre-menopau		opausal	pausal Post-menopausal			Total		
HDL	Ν	%	Ν	%	Ν	%		
<=40	7	30.43	6	22.22	13	26.00		
41-45	2	8.70	4	14.81	6	12.00		
46-50	6	26.09	4	14.81	10	20.00		
51-55	5	21.74	9	33.33	14	28.00		
>55	3	13.04	4	14.81	7	14.00		
Total	23	100	27	100	50	100.00		
Table 5								







